Efficacy and safety of pharmacological options for rate control in atrial fibrillation

AACN Advanced Critical Care

Volumn 23, Issue 2, 2012, Pages 120-125

  O'Brien, Katie ^a   Alexander, Earnest ^a   Patel, Lindsay ^a  

^a TAMPA GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN;

ARTICLE; CONTINUING EDUCATION; HEART ATRIUM FIBRILLATION; HEART CONTRACTION; HEART RATE; HUMAN; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; DIGOXIN; EDUCATION, CONTINUING; HEART RATE; HUMANS; MYOCARDIAL CONTRACTION;

EID: 84860786093     PISSN: 15597768     EISSN: 15597776     Source Type: Journal    
DOI: 10.1097/NCI.0b013e318242fdd0     Document Type: Article

References (11)

1. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-1539.
2. Flegel KM, Shipley MJ, Rose G. Risk of stroke in nonrheumatic atrial fibrillation. Lancet. 1987;1:526-529. (Pubitemid 17020736)
3. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43: 1201-1208. (Pubitemid 38452597)
4. Wattanasuwan N, Khan IA, Mehta NJ, et al. Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs IV diltiazem alone. CHEST. 2001;119:502-506. (Pubitemid 32163763)
5. Opie LH. Drugs and the heart. Lancet. 1980;1(8170): 693-698. (Pubitemid 10131690)
6. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989;63:925-929. (Pubitemid 19105127)
7. Fuster V, Ryden LE, Ainger RW, et al; and American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257-e354.
8. Lee J, Kim K, Lee CC, et al. Low-dose dilt iazem in atrial fibrillation with rapid ventricular response. Am J Emerg Med. 2011;29(8):849-854.
9. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med. 1997;29:135-140. (Pubitemid 27030029)
10. Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, et al. Rate control efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure: background, aims, and design of RACE II. Am Heart J. 2006;152:420-426. (Pubitemid 44233429)
11. Wann SL, Curtis AB, Crait T, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2011;8:157-176.